Cost-effectiveness analysis of nivolumab for the treatment of squamous cell carcinoma of the head and neck in the United States
Robert I. Haddad(Georgetown University), Kevin J. Harrington(Royal Marsden NHS Foundation Trust), Prianka Singh(Bristol-Myers Squibb (United States)), Beata Korytowsky(Pfizer (United States)), Kate Young(Merck & Co., Inc., Rahway, NJ, USA (United States)), M. Venkatachalam(PAREXEL International (United States)), Ezra E.W. Cohen(Moores Cancer Center), Pranav Abraham(Jain University), James W. Shaw(University of Illinois Chicago)
Cited by 28
Related Papers
Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck
|New England Journal of Medicine|2016|5.1k
Cisplatin and Fluorouracil Alone or with Docetaxel in Head and Neck Cancer
|New England Journal of Medicine|2007|1.7k
Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study
|The Lancet|2018|1.7k
Head and Neck Cancers, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2020|1.4k
Recent Advances in Head and Neck Cancer
|New England Journal of Medicine|2008|926